Cargando…
A mathematical model for treatment using chemo-immunotherapy
In this study, we investigated a mathematical model for chemoimmunotherapy (a combination of chemotherapy and immunotherapy) for brain cancer. In most cases, the standard protocol for cancer treatment is fixed in terms of treatment time intervals and dosages. We offer a wide range of non-fixed proto...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065634/ https://www.ncbi.nlm.nih.gov/pubmed/35520602 http://dx.doi.org/10.1016/j.heliyon.2022.e09288 |
_version_ | 1784699626474962944 |
---|---|
author | Nave, Ophir |
author_facet | Nave, Ophir |
author_sort | Nave, Ophir |
collection | PubMed |
description | In this study, we investigated a mathematical model for chemoimmunotherapy (a combination of chemotherapy and immunotherapy) for brain cancer. In most cases, the standard protocol for cancer treatment is fixed in terms of treatment time intervals and dosages. We offer a wide range of non-fixed protocols, which essentially vary in terms of time intervals and dosages (i.e., personalised medicine). The functions that describe this treatment are explicit and analytical. Hence, the parameters of the function can be easily changed and a new protocol can be obtained. We compared different protocols and obtained an optimal solution. In addition, we applied the singular perturbed vector field (SPVF) method to determine the hierarchy of the system of equations, which enabled us to identify the equilibrium points of the mathematical model and investigate their stability. |
format | Online Article Text |
id | pubmed-9065634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90656342022-05-04 A mathematical model for treatment using chemo-immunotherapy Nave, Ophir Heliyon Research Article In this study, we investigated a mathematical model for chemoimmunotherapy (a combination of chemotherapy and immunotherapy) for brain cancer. In most cases, the standard protocol for cancer treatment is fixed in terms of treatment time intervals and dosages. We offer a wide range of non-fixed protocols, which essentially vary in terms of time intervals and dosages (i.e., personalised medicine). The functions that describe this treatment are explicit and analytical. Hence, the parameters of the function can be easily changed and a new protocol can be obtained. We compared different protocols and obtained an optimal solution. In addition, we applied the singular perturbed vector field (SPVF) method to determine the hierarchy of the system of equations, which enabled us to identify the equilibrium points of the mathematical model and investigate their stability. Elsevier 2022-04-26 /pmc/articles/PMC9065634/ /pubmed/35520602 http://dx.doi.org/10.1016/j.heliyon.2022.e09288 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Nave, Ophir A mathematical model for treatment using chemo-immunotherapy |
title | A mathematical model for treatment using chemo-immunotherapy |
title_full | A mathematical model for treatment using chemo-immunotherapy |
title_fullStr | A mathematical model for treatment using chemo-immunotherapy |
title_full_unstemmed | A mathematical model for treatment using chemo-immunotherapy |
title_short | A mathematical model for treatment using chemo-immunotherapy |
title_sort | mathematical model for treatment using chemo-immunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065634/ https://www.ncbi.nlm.nih.gov/pubmed/35520602 http://dx.doi.org/10.1016/j.heliyon.2022.e09288 |
work_keys_str_mv | AT naveophir amathematicalmodelfortreatmentusingchemoimmunotherapy AT naveophir mathematicalmodelfortreatmentusingchemoimmunotherapy |